Enzymotec (ENZY) Misses Q4 EPS by 2c; Issues Light GY15 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Enzymotec Ltd. Reports Fourth Quarter and Full Year 2014 Unaudited Financial Results
February 18, 2015 7:30 AM ESTMIGDAL HA'EMEQ, Israel, Feb. 18, 2015 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq: ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients and medical foods, today reported its financial results for the fourth quarter and full year ended December 31, 2014.
Fourth Quarter 2014 Financial Highlights:
Company continues to see recovery as revenues increased significantly for the second consecutive quarter on a sequential basis; Fourth quarter net revenues (equity method) decreased 41.8% to $10.8 million, compared to the fourth quarter of 2013, but increased 13.4% compared to the third quarter of 2014; Fourth quarter net revenues (proportionate... More